Currently, 25% of Sun’s business comes from the Indian market, adding Rs. 7,000 crore to the total revenue kitty of Rs. 25,000 crore.
Following its $3.2billion acquisition of Ranbaxy Labs, Sun Pharma is contemplating a rationalization of its manufacturing network in the merged entity. With Ranbaxy in its fold, Sun’s staff strength has reached 30,000. Of the combined manufacturing plants numbering 45, 21 plants belong to Ranbaxy.
It is reliably learnt that many senior Ranbaxy executives have been shown the door in the new scheme of things. In an official statement, Sun has informed that an appropriate role for Ranbaxy’s erstwhile head Arun Sawhney is being explored. While denying the possibility of further acquisitions, the company has stated that it would definitely look at expanding into emerging markets. Going forward, Ranbaxy will look to strike a balance between domestic and international growth.
Currently, 25% of Sun’s business comes from the Indian market, adding Rs. 7,000 crore to the total revenue kitty of Rs.25000 crore. Of its 30,000 employees, around 8000-9000 are focused on India. Sun Pharma has also identified statutory compliance as a key focus area. It may be recalled that Ranbaxy is currently facing a US FDA import ban over alleged manufacturing violations. As part of the rationalization hence, the company is investing in training people, enhancing checks and controls and strengthening internal audits.
It is reliably learnt that many senior Ranbaxy executives have been shown the door in the new scheme of things. In an official statement, Sun has informed that an appropriate role for Ranbaxy’s erstwhile head Arun Sawhney is being explored. While denying the possibility of further acquisitions, the company has stated that it would definitely look at expanding into emerging markets. Going forward, Ranbaxy will look to strike a balance between domestic and international growth.
Currently, 25% of Sun’s business comes from the Indian market, adding Rs. 7,000 crore to the total revenue kitty of Rs.25000 crore. Of its 30,000 employees, around 8000-9000 are focused on India. Sun Pharma has also identified statutory compliance as a key focus area. It may be recalled that Ranbaxy is currently facing a US FDA import ban over alleged manufacturing violations. As part of the rationalization hence, the company is investing in training people, enhancing checks and controls and strengthening internal audits.
No comments:
Post a Comment